Literature DB >> 26922224

4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP).

Erden Banoglu1, Erşan Çelikoğlu2, Susanna Völker3, Abdurrahman Olgaç2, Jana Gerstmeier4, Ulrike Garscha4, Burcu Çalışkan2, Ulrich S Schubert5, Andrea Carotti6, Antonio Macchiarulo6, Oliver Werz3.   

Abstract

In this article, we report novel leukotriene (LT) biosynthesis inhibitors that may target 5-lipoxygenase-activating protein (FLAP) based on the previously identified isoxazole derivative (8). The design and synthesis was directed towards a subset of 4,5-diaryl-isoxazole-3-carboxylic acid derivatives as LT biosynthesis inhibitors. Biological evaluation disclosed a new skeleton of potential anti-inflammatory agents, exemplified by 39 and 40, which potently inhibit cellular 5-LO product synthesis (IC50 = 0.24 μM, each) seemingly by targeting FLAP with weak inhibition on 5-LO (IC50 ≥ 8 μM). Docking studies and molecular dynamic simulations with 5-LO and FLAP provide valuable insights into potential binding modes of the inhibitors. Together, these diaryl-isoxazol-3-carboxylic acids may possess potential as leads for development of effective anti-inflammatory drugs through inhibition of LT biosynthesis.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  5-lipoxygenase; 5-lipoxygenase-activating protein; Inflammation; Isoxazole; Leukotrienes

Mesh:

Substances:

Year:  2016        PMID: 26922224     DOI: 10.1016/j.ejmech.2016.02.027

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  Crystal structure and Hirshfeld surface analysis of 4-(4-chloro-phen-yl)-5-methyl-3-{4-[(2-methyl-phen-yl)meth-oxy]phen-yl}-1,2-oxazole.

Authors:  Abdullah Aydin; Mehmet Akkurt; Sumeyye Turanli; Deniz Lengerli; Erden Banoglu; Nefise Dilek Ozcelik
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2021-03-05

Review 2.  Recent development of lipoxygenase inhibitors as anti-inflammatory agents.

Authors:  Chaoyu Hu; Shutao Ma
Journal:  Medchemcomm       Date:  2017-11-29       Impact factor: 3.597

3.  Encapsulation of the dual FLAP/mPEGS-1 inhibitor BRP-187 into acetalated dextran and PLGA nanoparticles improves its cellular bioactivity.

Authors:  Blerina Shkodra-Pula; Christian Kretzer; Paul M Jordan; Paul Klemm; Andreas Koeberle; David Pretzel; Erden Banoglu; Stefan Lorkowski; Maria Wallert; Stephanie Höppener; Steffi Stumpf; Antje Vollrath; Stephanie Schubert; Oliver Werz; Ulrich S Schubert
Journal:  J Nanobiotechnology       Date:  2020-05-14       Impact factor: 10.435

4.  Synthesis, Physicochemical Characteristics and Plausible Mechanism of Action of an Immunosuppressive Isoxazolo[5,4-e]-1,2,4-Triazepine Derivative (RM33).

Authors:  Marcin Mączyński; Andrzej Regiec; Aleksandra Sochacka-Ćwikła; Iwona Kochanowska; Maja Kocięba; Ewa Zaczyńska; Jolanta Artym; Wojciech Kałas; Michał Zimecki
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-15

Review 5.  Isoxazole Derivatives as Regulators of Immune Functions.

Authors:  Michał Zimecki; Urszula Bąchor; Marcin Mączyński
Journal:  Molecules       Date:  2018-10-22       Impact factor: 4.411

6.  Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents.

Authors:  Burcu Çalışkan; Esra Sinoplu; Kübra İbiş; Ece Akhan Güzelcan; Rengül Çetin Atalay; Erden Banoglu
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.